On January 20, 2023 EpicentRx, Inc, a leading-edge, clinical-stage biopharmaceutical company that uses groundbreaking science to treat cancer and inflammatory-driven diseases, reported data from a Phase 2 randomized clinical trial of RRx-001 vs. regorafenib in patients with third/fourth line colorectal cancer has been selected for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium being held January 19-21 in San Francisco (Press release, EpicentRx, JAN 20, 2023, View Source [SID1234626417]). The Phase 2 study, called ROCKET, compares the safety and efficacy of RRx-001 plus irinotecan vs. regorafenib in 34 patients with third/fourth line colorectal cancer that were previously treated with irinotecan-based therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Positive results from the completed Phase 2 study demonstrate improved overall survival and significantly improved progression free survival of RRx-001 plus irinotecan compared with regorafenib in 3rd/4th line colorectal cancer. ROCKET was carried out in collaboration with Dr. George Fisher from Stanford and Dr. Keola Beale from Kaiser Permanente Moanalua Medical Center.
Details on the company’s poster presentation are below:
Abstract Title: ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 vs. regorafenib in Third/Fourth Line Colorectal Cancer
Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus
Abstract Number for Publication: 97
Session Date and Time: Saturday, January 21, 2023: 6:30 AM – 7:55 AM
About RRx-001
RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies. RRx-001 is under investigation in a Phase 3 trial for the treatment of small cell lung cancer (SCLC), and in a Phase 2 trial for protection against oral mucositis in first line head and neck cancer. It is also under development as a medical countermeasure for nuclear and radiological emergencies and as a treatment for neurodegenerative diseases like Parkinson’s and ALS/MND.